ArticleClinical & developmental immunology2007
Attenuated disease in SIV-infected macaques treated with a monoclonal antibody against FasL.
Article in Clinical & developmental immunology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 19 citations in OpenAlex.
- Type I interferon upregulates Bak and contributes to T cell loss during human immunodeficiency virus (HIV) infection.PLoS pathogens · 2013Trial
- FAS mediates apoptosis, inflammation, and treatment of pathogen infection.Frontiers in cellular and infection microbiology · 2025Review
- Plasmacytoid dendritic cells mediate synergistic effects of HIV and lipopolysaccharide on CD27+ IgD- memory B cell apoptosis.Journal of virology · 2014Article
- Microbial TLR Agonists and Humoral Immunopathogenesis in HIV Disease.Epidemiology (Sunnyvale, Calif.) · 2013Article
- Microbial Translocation and B Cell Dysfunction in Human Immunodeficiency Virus Disease.American journal of immunology · 2012Article
- Article
- Lymphocytic choriomeningitis virus (LCMV) infection of macaques: a model for Lassa fever.Antiviral research · 2011Review
- The cytokine network of acute HIV infection: a promising target for vaccines and therapy to reduce viral set-point?PLoS pathogens · 2011Review
- Mechanisms of HIV-associated lymphocyte apoptosis: 2010.Cell death & disease · 2010Review
- Acute depletion of activated memory B cells involves the PD-1 pathway in rapidly progressing SIV-infected macaques.The Journal of clinical investigation · 2010Article
- Temporal association of large granular lymphocytosis, neutropenia, proviral load, and FasL mRNA in cats with acute feline immunodeficiency virus infection.Veterinary immunology and immunopathology · 2010Article
- Virion-associated Vpr of human immunodeficiency virus type 1 triggers activation of apoptotic events and enhances fas-induced apoptosis in human T cells.Journal of virology · 2009Article
- Role of the Fas/FasL pathway in HIV or SIV disease.Retrovirology · 2009Review
- Article
- Impacts of HIV infection on Vgamma2Vdelta2 T cell phenotype and function: a mechanism for reduced tumor immunity in AIDS.Journal of leukocyte biology · 2008Article
- Induction of plasma (TRAIL), TNFR-2, Fas ligand, and plasma microparticles after human immunodeficiency virus type 1 (HIV-1) transmission: implications for HIV-1 vaccine design.Journal of virology · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 2 countries.
Funding
Abstract
Acute SIVmac infection in macaques is accompanied by high levels of plasma viremia that decline with the appearance of viral immunity and is a model for acute HIV disease in man. Despite specific immune responses, the virus establishes a chronic, persistent infection. The destruction of CD4+ and CD4- lymphocyte subsets in macaques contributes to viral persistence and suggests the importance of mechanisms for depleting both infected and uninfected (bystander) cells. Bystander cell killing can occur when FasL binds the Fas receptor on activated lymphocytes, which include T and B cell subpopulations that are responding to the infection. Destruction of specific immune cells could be an important mechanism for blunting viral immunity and establishing persistent infection with chronic disease. We inhibited the Fas pathway in vivo with a monoclonal antibody against FasL (RNOK203). Here we show that treatment with anti-FasL reduced cell death in circulating T and B cells, increased CTL and antibody responses to viral proteins, and lowered the setpoint viremia. By blocking FasL during only the first few weeks after infection, we attenuated SIVmac disease and increased the life span for infected and treated macaques.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.